Back to all studies
CompletedNCT02181803

Safety study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8189 in schizophrenia

This study is completed. It is testing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8189 for schizophrenia.

SchizophreniaBehavioralFrom 18 Years to 60 Years

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Then choose your country and confirm availability with each study site.

In plain English

Key information made simple

This summary needs review. Please check the official study record and contact the research team for details.

Your next step

Check the study details

Check the official source, then confirm these points with the research team.

View official study record (opens in a new tab)
  • Recruitment and eligibility

    Is a site open, and who can take part?

  • Visits and time

    Where are visits, can any be remote, and how much time is needed?

  • Costs and support

    What costs, reimbursement or compensation apply?

Before joining

Questions to ask before joining

Study clarity

Things to check before joining

Study start dateStarted: August 5, 2014
Recruitment status
Completed
Enrollment listed in the registry
55
Sponsor
Merck Sharp & Dohme LLC
Sponsor type
Other organization
Study type
Behavioral
Intervention type
Medication / drug
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Locations
Not clearly listed
Age range
From 18 Years to 60 Years
Official registry ID
NCT02181803
Official title
A Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8189 in Healthy Volunteers and in Schizophrenia Patients

Check recruitment and locations

Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.

View official study record (opens in a new tab)

No specific site is confirmed in the available information. Check the official source for locations and remote participation.

Ask HopeStage to help me review this study

This record does not confirm open recruitment. We can help you understand it and explore other studies.

Loading the security check...
Study ID: NCT02181803. We help you review the study, but cannot decide medical eligibility.
In practice

For you

Participation may contribute to research. Personal benefit is not guaranteed.

Ask the research team to explain the activities, time commitment, and follow-up involved.

Confirm the location and whether remote participation is possible with the research team.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What is this study trying to understand?

This study is exploring psychotherapy or therapy for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.

What is a behavioral study?

This appears to be a behavioral / psychological / psychosocial study involving Elpipodect, Placebo, Base Monotherapy. Phase 1 studies usually focus mainly on safety, tolerability, dosage, and side effects. They often involve healthy volunteers, but not always. Some Phase 1 studies include people living with the target condition.

Who might this study be for?

This study may concern people with schizophrenia; age range: From 18 Years to 60 Years. The criteria appear fairly specific, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.

What would I likely need to do?

You may take part in sessions or exercises related to habits, thoughts, emotions, or behaviors. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.

Could this study affect my mood, habits, motivation, or stress?

Behavioral studies can involve habits, emotions, motivation, stress, sleep, or ways of thinking. Ask whether the intervention could affect your mood or stress, and who to contact if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.

Will I need to travel or attend in-person visits?

The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.

Who is behind this study?

This study is sponsored by Merck Sharp & Dohme LLC, which appears to be another type of organization. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.

Can I still join this study?

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me